<i>Pityrosporum</i> folliculitis in critically ill COVID‐19 patients

Peres, Fernanda Lagares Xavier; Bonamigo, Renan Rangel; Bottega, Gustavo Borchardt; Staub, Fernanda Luiza; Cartell, André; Renato, Bakos Marchiori

doi:10.1111/jdv.17842

Cited by 5 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tsai et al (2018) found atypical presentations of PF in a cohort of 22/94 patients in a retrospective cohort; atypical presentation consisted of less papules, atypical macules/patches in 6/22 (27.3%), or plaques in 4/22 patients (18.2%) [ 16 ]. Tsai et al (2019) found differences in pediatric versus adult PF, with pediatric patients showing significantly more PF on the face ( n = 17/79, 21.5% pediatric; n = 28/242, 11.6% adults, p = 0.027); both age groups showed PF more commonly in males and occurring during summer months [ 17 ].…”

Section: Resultsmentioning

confidence: 99%

Clinical characteristics and treatment outcomes of Pityrosporum folliculitis in immunocompetent patients

et al. 2022

View full text Add to dashboard Cite

Pityrosporum folliculitis (PF) is a fungal acneiform disease of the hair follicles that often presents with pruritic papules and pustules on the upper body and face . This condition is commonly mistaken for acne vulgaris and can be distinguished from bacterial acne by the presence of fungal spores in the follicular lumen . Although studies have been performed to describe PF in cohorts, little work has been done to aggregate these data. Thus, the goal of this review is to describe the clinical characteristics and treatment outcomes of PF in immunocompetent patients. PubMed, Web of Science, and Embase were searched using the terms “Pityrosporum folliculitis” or “Malassezia folliculitis.” All cohorts reporting PF characteristics in patients classified as immunocompetent were reviewed. A total of 15 studies were included. Majority of patients were male (64%) with the average age of presentation of 24.26 years. The most common locations of lesions were the chest (70%) and back/shoulders (69.2%). Pruritus was reported by the majority of patients (71.7%). Additionally, 40.5% of patients reported a history of unsuccessful treatment regimens. Treatment was most successful with an oral antifungal (92%), followed by a topical antifungal (81.6%). In conclusion, majority of patients with PF were younger males. Many patients were primarily treated incorrectly, suggesting the importance of proper diagnosis. PF may be distinguishable from acne vulgaris by the presence of pruritus or suggested when a new acneiform eruption develops following antibiotic therapy or immunosuppression. When properly diagnosed, majority of cases of PF achieve complete response with oral or topical antifungals.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical characteristics and treatment outcomes of Pityrosporum folliculitis in immunocompetent patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Cases of severe infections caused by rare yeasts from Bolivia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Haiti, Honduras, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, and Uruguay have not been reported until now (Figure 1). From the species of rare yeasts, 396 (80%) were identified to the species level, accounting for 32 species, distributed in 12 genera: Geotrichum candidum [19][20][21], Kloeckera apiculata (Hanseniaspora uvarum) [17], Kodamaea ohmeri [22][23][24][25], Magnusiomyces capitatus (Geotrichum capitatum, Saprochaete capitata, Blastoschizomyces capitatus) [26][27][28][29][30], Malassezia furfur [18,[31][32][33][34][35], Malassezia pachydermatis [36], Malassezia sympodialis [34,37,38], Millerozyma farinosa (Pichia farinosa) [39], Pichia angusta (Hansenula polymorpha) [40], Pichia anomala (Wickerhamomyces anomalus) [40,41], Pseudozyma aphidis [42,43], Rhodotorula dairenensis [44], Rhodotorula glutinis [15,34,39,45,46], Rhodotorula minuta (Cystobasidium minutum) [44,47], Rhodotorula mucilaginosa (Rhodotorula rubra) [40,44,46,…”

Section: Species Of Rare Yeastsmentioning

confidence: 99%

Rare Yeasts in Latin America: Uncommon Yet Meaningful

Gil,

Hernández-Pabón,

Tabares

et al. 2023

JoF

View full text Add to dashboard Cite

Systemic infections caused by rare yeasts are increasing given the rise in immunocompromised or seriously ill patients. Even though globally, the clinical significance of these emerging opportunistic yeasts is increasingly being recognized, less is known about the epidemiology of rare yeasts in Latin America. This review collects, analyzes, and contributes demographic and clinical data from 495 cases of infection caused by rare yeasts in the region. Among all cases, 32 species of rare yeasts, distributed in 12 genera, have been reported in 8 Latin American countries, with Trichosporon asahii (49.5%), Rhodotorula mucilaginosa (11.1%), and Saccharomyces cerevisiae (7.8%) the most common species found. Patients were mostly male (58.3%), from neonates to 84 years of age. Statistically, surgery and antibiotic use were associated with higher rates of Trichosporon infections, while central venous catheter, leukemia, and cancer were associated with higher rates of Rhodotorula infections. From all cases, fungemia was the predominant diagnosis (50.3%). Patients were mostly treated with amphotericin B (58.7%). Crude mortality was 40.8%, with a higher risk of death from fungemia and T. asahii infections. Culture was the main diagnostic methodology. Antifungal resistance to one or more drugs was reported in various species of rare yeasts.

show abstract

“…In Japan, three obese men with SARS-CoV-2 co-infection, aged 39, 46, and 52 years, were diagnosed by histological examination with chronic suppurative folliculitis with Malassezia species. The first two possessed no other comorbidities and the third was type 2 diabetic; the three used systemic corticosteroids [111].…”

Section: Malassezia Sppmentioning

confidence: 99%

Clinical Challenges of Emerging and Re-Emerging Yeast Infections in the Context of the COVID-19 Pandemic

et al. 2022

View full text Add to dashboard Cite

During the geological eras, some fungi, through adaptation and/or environmental/ecological pressure, interacted directly and indirectly with humans, through occasionally harmful interaction interdependent on the individual’s immunological condition. Infections caused by yeasts are underreported, subjugated, and underdiagnosed, and treatment is restricted to a few drugs, even after the significant progress of medicine and pharmacology. In the last centuries, antagonistically, there has been an exponential increase of immunocompromised individuals due to the use of immunosuppressive drugs such as corticosteroids, increased cases of transplants, chemotherapeutics, autoimmune diseases, neoplasms, and, more recently, coronavirus disease 2019 (COVID-19). This review aims to survey emerging and re-emerging yeast infections in the current clinical context. Currently, there is an immense clinical challenge for the rapid and correct diagnosis and treatment of systemic mycoses caused by yeasts due to the terrible increase in cases in the current context of COVID-19.

show abstract

Pityrosporum folliculitis in critically ill COVID‐19 patients

Cited by 5 publications

References 8 publications

Clinical characteristics and treatment outcomes of Pityrosporum folliculitis in immunocompetent patients

Clinical characteristics and treatment outcomes of Pityrosporum folliculitis in immunocompetent patients

Rare Yeasts in Latin America: Uncommon Yet Meaningful

Clinical Challenges of Emerging and Re-Emerging Yeast Infections in the Context of the COVID-19 Pandemic

Contact Info

Product

Resources

About